TY - JOUR
T1 - Cardiac resynchronization therapy in patients with mild heart failure
T2 - A systematic review and meta-analysis
AU - Santangeli, Pasquale
AU - Di Biase, Luigi
AU - Pelargonio, Gemma
AU - Dello Russo, Antonio
AU - Casella, Michela
AU - Bartoletti, Stefano
AU - David Burkhardt, J.
AU - Mohanty, Prasant
AU - Santarelli, Pietro
AU - Natale, Andrea
N1 - Funding Information:
Conflicts of interest Dr. Andrea Natale has received compensation for belonging to the speakers’ bureau for St. Jude Medical, Boston Scientific, Medtronic, and Biosense Webster and has received a research grant from St. Jude Medical. The other authors declare no conflicts of interest.
PY - 2011/11
Y1 - 2011/11
N2 - Purpose: Cardiac resynchronization therapy (CRT) reduces symptoms and improves survival in patients with advanced heart failure (New York Heart Association (NYHA) functional class III-IV), reduced ejection fraction, and wide QRS complex. Whether CRT has the same benefit also in asymptomatic or mildly symptomatic heart failure patients is controversial. Our objective is to summarize the available evidence on the effects of CRT in asymptomatic or mildly symptomatic (NYHA I-II) heart failure patients. Methods: We searched major web databases for randomized controlled trials of CRT in patients with mild heart failure (NYHA functional class I-II). Data regarding all-cause mortality, heart failure events, left ventricular (LV) volumes and ejection fraction, and worsening of NYHA functional class were extracted. Results: We identified five trials (CONTAK-CD, MIRACLE ICD-II, REVERSE, MADIT-CRT, and RAFT) that enrolled 4,213 patients (91% with NYHA II functional class). Primary analysis excluded the CONTAK-CD, which was not specifically conducted on patients with mild heart failure. At pooled analysis, CRT decreased mortality (odds ratio (OR), 0.78 [95% confidence interval (CI)], 0.63 to 0.97; p=0.024) and heart failure events (OR, 0.63 [95% CI, 0.52 to 0.76], p<0.001), induced a significant LV reverse remodeling (weighted mean difference (WMD) of LV ejection fraction =+4.8%[95% CI, + 0.9 to+ 8.7%], p=0.015 and WMD of LV end-systolic volume index = -19.4mL/m 2[95%CI, - 18.2 to - 20.7mL/m 2], p<0.001) and prevented the progression of heart failure symptoms (OR for worsening of NYHA functional class= 0.54 [95% CI, 0.31 to 0.93], p=0.026). Inclusion of the CONTAK-CD did not change the results. Conclusions: Among patients with mild (NYHA II) heart failure, CRT reduces mortality and the risk of heart failure events, induces a favorable LV reverse remodeling and slows the progression of heart failure symptoms.
AB - Purpose: Cardiac resynchronization therapy (CRT) reduces symptoms and improves survival in patients with advanced heart failure (New York Heart Association (NYHA) functional class III-IV), reduced ejection fraction, and wide QRS complex. Whether CRT has the same benefit also in asymptomatic or mildly symptomatic heart failure patients is controversial. Our objective is to summarize the available evidence on the effects of CRT in asymptomatic or mildly symptomatic (NYHA I-II) heart failure patients. Methods: We searched major web databases for randomized controlled trials of CRT in patients with mild heart failure (NYHA functional class I-II). Data regarding all-cause mortality, heart failure events, left ventricular (LV) volumes and ejection fraction, and worsening of NYHA functional class were extracted. Results: We identified five trials (CONTAK-CD, MIRACLE ICD-II, REVERSE, MADIT-CRT, and RAFT) that enrolled 4,213 patients (91% with NYHA II functional class). Primary analysis excluded the CONTAK-CD, which was not specifically conducted on patients with mild heart failure. At pooled analysis, CRT decreased mortality (odds ratio (OR), 0.78 [95% confidence interval (CI)], 0.63 to 0.97; p=0.024) and heart failure events (OR, 0.63 [95% CI, 0.52 to 0.76], p<0.001), induced a significant LV reverse remodeling (weighted mean difference (WMD) of LV ejection fraction =+4.8%[95% CI, + 0.9 to+ 8.7%], p=0.015 and WMD of LV end-systolic volume index = -19.4mL/m 2[95%CI, - 18.2 to - 20.7mL/m 2], p<0.001) and prevented the progression of heart failure symptoms (OR for worsening of NYHA functional class= 0.54 [95% CI, 0.31 to 0.93], p=0.026). Inclusion of the CONTAK-CD did not change the results. Conclusions: Among patients with mild (NYHA II) heart failure, CRT reduces mortality and the risk of heart failure events, induces a favorable LV reverse remodeling and slows the progression of heart failure symptoms.
KW - Cardiac resynchronization therapy
KW - Left ventricular reverse remodeling
KW - Mild heart failure
UR - http://www.scopus.com/inward/record.url?scp=84855567078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855567078&partnerID=8YFLogxK
U2 - 10.1007/s10840-011-9584-y
DO - 10.1007/s10840-011-9584-y
M3 - Review article
C2 - 21594629
AN - SCOPUS:84855567078
SN - 1383-875X
VL - 32
SP - 125
EP - 135
JO - Journal of Interventional Cardiac Electrophysiology
JF - Journal of Interventional Cardiac Electrophysiology
IS - 2
ER -